Last checked at 22 Nov 2022 10:50
22 November 2022
N4 Pharma plc
("N4 Pharma" or the "Company")
Result of Broker Offer
Total Voting Rights
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, announces that, further to the announcement made on 18 November 2022, the Broker Offer, a facility to allow existing shareholders and other interested parties to participate on the same terms to the Placing announced on 18 November 2022, has now closed having raised a gross amount of £54,000, resulting in the issue by the Company of an additional 2,700,000 new ordinary shares of 0.4 pence each ("Broker Offer Shares").
Broker Warrants
As part of its fee, TPI will be issued with warrants ("Broker Warrants") to subscribe for 3,162,000 new ordinary shares exercisable at the Issue Price of 2 pence each, equivalent to 6 (six) per cent. of the gross aggregate value of funds raised in the Placing and Broker Offer. The Broker Warrants have a term of 36 months from the date of admission of the Broker Offer Shares to trading on AIM and are being issued under the Company's existing share authorities.
Application for Admission
Application has been made for the Broker Offer Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will take place at 8.00 a.m. on or around 25 November 2022. The Broker Offer Shares will rank pari passu with the Company's existing ordinary shares.
Total Voting Rights
Following Admission of the Broker Offer Shares, the enlarged issued share capital of the Company will comprise 233,780,349 ordinary shares of 0.4 pence each. The Company does not hold any ordinary shares in treasury. Consequently, 233,780,349 is the figure which may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.
Terms and definitions in this notification are as defined in the notification of 18 November 2022.
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 which has been incorporated into UK law by the European Union (Withdrawal) Act 2018. Upon the publication of this announcement via Regulatory Information Service, this inside information is now considered to be in the public domain.
Enquiries:
N4 Pharma plc |
|
Nigel Theobald, CEO | Via IFC Advisory |
Luke Cairns, Executive Director | |
|
|
SP Angel Corporate Finance LLP | Tel: +44(0)20 3470 0470 |
Nominated Adviser and Joint Broker | |
Matthew Johnson/Caroline Rowe (Corporate Finance) | |
Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking) | |
|
|
Turner Pope Investments (TPI) Limited | Tel: +44(0)20 3657 0050 |
Joint Broker | |
Andy Thacker James Pope | |
| |
IFC Advisory Ltd | Tel: +44(0)20 3934 6630 |
Financial PR | |
Graham Herring | |
Zach Cohen | |
|
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.
N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through preclinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.